Prostate Specific Antigen News and Research RSS Feed - Prostate Specific Antigen News and Research

VALIDATE D-Dimer kit from LGC Maine Standards receives US FDA approval for use on hemostasis test systems

VALIDATE D-Dimer kit from LGC Maine Standards receives US FDA approval for use on hemostasis test systems

LGC Maine Standards is pleased to announce our VALIDATE D-Dimer calibration verification / linearity test kit has received US FDA 510(k) clearance for use on Instrument Laboratory ACL TOP hemostasis test systems. [More]
Management of prostate cancer varies by race

Management of prostate cancer varies by race

A study published in The Journal of Urology® indicates that treatment for low-risk prostate cancer, rather than watchful waiting, is most likely to be sought by black men. [More]
Active surveillance improves health related quality of life in low risk prostate cancer patients

Active surveillance improves health related quality of life in low risk prostate cancer patients

Active surveillance (AS) has become an increasingly important alternative to surgery, chemotherapy, or radiation treatment for men diagnosed with low risk prostate cancer. [More]
VCU Health radiologist uses MRI technology to detect difficult prostate cancers

VCU Health radiologist uses MRI technology to detect difficult prostate cancers

For three years, Andrew Harder wondered if he had prostate cancer. In 2009, he had routine blood work that revealed an elevated prostate-specific antigen (PSA) level. [More]
New study reports significant increase in new metastatic prostate cancer cases

New study reports significant increase in new metastatic prostate cancer cases

The number of new cases of metastatic prostate cancer climbed 72 percent in the past decade from 2004 to 2013, reports a new Northwestern Medicine study. [More]
Study finds evidence that PD-1 antibody may benefit men with metastatic prostate cancer

Study finds evidence that PD-1 antibody may benefit men with metastatic prostate cancer

Restoring tumor-specific immunity is a treatment strategy that works well in melanoma and lung cancer patients. Now a new study out of the OHSU Knight Cancer Institute is reviving hope that the approach also may help men with life-threatening prostate cancer. [More]
Phase III clinical study of promising prostate cancer drug reveals surprising results

Phase III clinical study of promising prostate cancer drug reveals surprising results

A recently published international clinical Phase III trial of a promising drug for treating advanced prostate cancer ended with surprising results: the new therapeutic agent failed to achieve any significant improvement in the overall survival of patients compared with the established standard treatment. [More]
Changes in benign tissue adjacent to prostate tumors could better predict recurrence

Changes in benign tissue adjacent to prostate tumors could better predict recurrence

Changes in benign tissues next to prostate tumors may provide an early warning for patients at higher risk for biochemical recurrence after a radical prostatectomy, a study by researchers at Case Western Reserve University and Johns Hopkins Medical Institutions shows. [More]
Scientists create protein signatures for accurate diagnosis of prostate cancer

Scientists create protein signatures for accurate diagnosis of prostate cancer

Researchers at the Ontario Institute for Cancer Research and University Health Network in Toronto, along with researchers at the Eastern Virginia Medical School, have created protein signatures that accurately diagnose prostate cancer and can distinguish between patients with aggressive versus non-aggressive disease using a simple urine sample. [More]
NYU Lutheran helps patients fight prostate cancer with latest diagnostic and robotic surgery technology

NYU Lutheran helps patients fight prostate cancer with latest diagnostic and robotic surgery technology

Leading NYU Lutheran's fight is Marc Bjurlin, DO, the hospital's newly appointed director of urologic oncology and clinical assistant professor of urology at NYU School of Medicine. [More]
Screening PSA levels in younger men could accurately predict future risk of prostate cancer

Screening PSA levels in younger men could accurately predict future risk of prostate cancer

Prostate cancer screening with prostate-specific antigen (PSA) has been shown to reduce death and the spread of prostate cancer to other parts of the body, but the PSA test remains highly controversial as it frequently leads to over diagnosis and over treatment of men who may not be at risk. [More]
NaF-PET/CT scans can accurately detect bone metastases in advanced prostate cancer patients

NaF-PET/CT scans can accurately detect bone metastases in advanced prostate cancer patients

A recent pilot study reported in the June issue of The Journal of Nuclear Medicine found that sodium fluoride (Na-F-18) positron emission tomography/computed tomography (NaF-PET/CT) accurately detects bone metastases in patients with advanced prostate cancer, and follow-up scans over time correlate clearly with clinical outcomes and patient survival. [More]
New clinical study data could redefine treatment for mCRPC patients

New clinical study data could redefine treatment for mCRPC patients

Janssen-Cilag International NV today announced that data from an interim analysis of The Prostate Cancer Registry, Europe’s first and largest prospective study of men with metastatic castration-resistant prostate cancer (mCRPC), indicate that the presence of distant metastases (M1) at initial diagnosis may be a critical indicator of future treatment and prognosis for mCRPC patients. [More]
Clinical trial to evaluate ability of MRI to improve prostate cancer diagnosis

Clinical trial to evaluate ability of MRI to improve prostate cancer diagnosis

The Movember Foundation, the Ontario Institute for Cancer Research and Prostate Cancer Canada today announced $3 million in funding for a new Phase III clinical trial to evaluate if magnetic resonance imaging (MRI) can replace the current standard of care to diagnose prostate cancer. [More]
Axumin approved for use in PET scans in patients with recurrent prostate cancer

Axumin approved for use in PET scans in patients with recurrent prostate cancer

The U.S. Food and Drug Administration today approved Axumin, a radioactive diagnostic agent for injection. Axumin is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated prostate specific antigen (PSA) levels following prior treatment. [More]
New IsoPSA test identifies molecular structural changes in protein biomarkers to detect prostate cancer

New IsoPSA test identifies molecular structural changes in protein biomarkers to detect prostate cancer

A promising new test is detecting prostate cancer more precisely than current tests, by identifying molecular changes in the prostate specific antigen (PSA) protein, according to Cleveland Clinic research presented today at the American Urological Association annual meeting. [More]
New model can increase active surveillance for low-risk prostate cancer patients

New model can increase active surveillance for low-risk prostate cancer patients

Urologists at University of California, San Diego School of Medicine and Genesis Healthcare Partners have tested a new model of care for patients with low-risk prostate cancer. The evidence-based approach uses best practices to appropriately select and follow patients to avoid disease overtreatment. Results of the three-year study are now published online in the journal of Urology. [More]
CWRU scientists develop computational tools to quantify effects of prostate cancer laser ablation

CWRU scientists develop computational tools to quantify effects of prostate cancer laser ablation

Prostate cancers are either low-grade, low-risk forms that may be monitored but otherwise untreated. Or they're serious enough to require surgery and radiation. [More]
Study assesses risk factors for metastases in prostate cancer patients on active surveillance

Study assesses risk factors for metastases in prostate cancer patients on active surveillance

Radical treatment such as surgery and radiation for localized prostate cancer may cause significant side effects. Active surveillance is increasingly accepted as an option for treating patients with clinically insignificant disease to maintain their quality of life. [More]
Experimental urine test identifies 92% of men with elevated PSA levels

Experimental urine test identifies 92% of men with elevated PSA levels

An experimental urine test that detects genetic changes associated with prostate cancer identified 92 percent of men with elevated PSA (prostate-specific antigen) levels who had high-grade cancers, according to a study published today in JAMA Oncology online. [More]
Advertisement
Advertisement